Compare DRMA & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRMA | SILO |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.6M |
| IPO Year | N/A | 2011 |
| Metric | DRMA | SILO |
|---|---|---|
| Price | $1.26 | $0.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 3.1M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.22 |
| 52 Week High | $7.33 | $1.18 |
| Indicator | DRMA | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 55.45 |
| Support Level | $1.13 | $0.40 |
| Resistance Level | $1.84 | $0.47 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 22.30 | 30.58 |
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.